Study Links Cognitive Behavioral Therapy for Insomnia to Slower Biological Aging
Insomnia is a prevalent sleep disorder in the United States, affecting approximately one-third of adults, with the incidence rising to 40% among those over 65 years. This condition can severely impact daily functioning, mood, cognition, and overall quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is often the first-line treatment, focusing on changing the thoughts and behaviors that contribute to sleep difficulties, without the side effects associated with medications.
A new study conducted by researchers at UCLA Health and published in The Lancet Healthy Longevity has found that CBT-I may offer additional benefits beyond improving sleep. The study indicates that older adults undergoing CBT-I showed a slower pace of biological aging, as measured by epigenetic clocks, compared to those receiving general sleep education.
The randomized controlled trial involved nearly 100 participants aged 60 and older who met the DSM-IV criteria for insomnia disorder. Participants were divided into two groups: one receiving CBT-I and the other receiving sleep education, which provided general information about sleep and healthy sleep habits. Results showed that those who received CBT-I were nearly three times more likely to achieve remission from insomnia than those in the control group.
The researchers measured biological aging by analyzing blood samples taken before the eight-week treatment and during follow-up visits over two years. They utilized three different measures of biological aging: DunedinPACE, GrimAge, and PC-PhenoAge. Notably, CBT-I was associated with a significant slowing in the pace of biological aging, particularly as indicated by the DunedinPACE measure.
However, the findings do not imply that CBT-I can reverse aging or make individuals biologically younger. Instead, the study observed a measurable difference in the rate of biological aging, with participants in the CBT-I group aging approximately 2% slower per year compared to their counterparts. Judith Carroll, PhD, the lead author of the study, emphasized the importance of treating insomnia not only for improved sleep but also for broader health protection.
While the results are promising, they do not establish a direct causal relationship between CBT-I and reduced biological aging or prevention of age-related diseases. The study's limitations include its small sample size and the recruitment of participants from a single location in Los Angeles, indicating a need for larger, more diverse studies to validate these findings.
The research also highlights the complex relationship between sleep and biological processes. Poor sleep may disrupt various health-related processes, including stress regulation, metabolism, and inflammation, potentially contributing to age-related diseases. Carroll noted that sleep is crucial for allowing the body to recover from daily stressors, and effective sleep management through CBT-I could positively influence biological aging pathways.
The study's findings suggest that treating insomnia might confer broader health benefits, although further investigation is required to explore the long-term effects of CBT-I on biological aging and whether different treatments for insomnia yield similar outcomes. Carroll concluded by emphasizing the need for continued research funding to explore these significant health questions further.




